Delhi Declaration: Improving access to life-saving medical devices in the Southeast Asia region and beyond. April 2018 Q. Is it important to create a training plan? I am trying to create a training plan ¦ ¦ Is it important to create a training plan? The list of medical countermeasures for devices includes diagnostic test kits and accessories for rapid test development and treatment, personal protective equipment, vital signs active surveillance devices, vaccine delivery devices, and devices to treat acute diseases such as ventilators. Countries in the WHO South-East Asia Region are deciding to make essential medical products accessible and affordable for all: in medicine, an unknown cause, as well as in essential hypertension (hypertension of unknown cause). Also known as idiopathic. Access to pain relief and life-saving opioids in the WHO South-East Asia Region: challenges in implementing drug reforms. Q. How do I know which important tools/instruments I need to buy for my baby? The criteria used by the FDA to identify essential drugs, medical countermeasures, and critical inputs are available here: The criteria for identifying drugs for human use and essential biologics, medical countermeasures, and critical inputs for the list of items described in Section 3(c) of Executive Order (EO) 13944 (PDF, 126KB) are selected as essential drugs, depending on: the frequency of the disease to be treated. Evidence of benefits, degree of side effects and costs compared to other options. [8] Accelerating access to essential medicines in the WHO South-East Asia Region: opportunities for greater engagement and better evidence. In general, the essential medicines we identify are the ones we need most for patients in U.S. acute care facilities who specialize in the short-term treatment of serious injuries or illnesses and urgent medical problems.
The medical countermeasures we identify are FDA-regulated products (biologics, drugs, devices) that meet the definition of a “medical countermeasure” in the executive order and that we believe will be necessary to respond to future chemical, biological, and radiological/nuclear pandemics, epidemics, and threats. In identifying essential medicines and medical countermeasures, we have focused on including those that are medically necessary to be available in adequate care that can be used for the widest population in order to have the greatest potential impact on public health. Access to Medical Devices in the Southeast Asia Region 2019: A Review of Progress Alcohol-based hand friction is not superior to soap and water, but more expensive. Daclatasvir and dasabuvir are investigational drugs for the treatment of hepatitis C infections, which find a place in the 19th Model List of Essential Medicines. The inclusion of investigational medicinal products runs counter to the fundamental purpose of the list of essential medicinal products. In addition, the clearance rate of the virus without treatment in acute hepatitis C is 15-30%. Antiviral therapy is recommended if viremia (documented by HCV RNA tests) persists 12 weeks after initial seroconversion. Protease inhibitors such as simeprevir are indicated for genotype 1 HCV infection and are not recommended for other HCV genotypes. How many centres around the world have facilities to measure HCV RNA levels and HCV genotype testing? Profitability is the subject of debate between manufacturers (pharmaceutical companies) and drug buyers (national health services).
It is estimated that access to life-saving medicines could save 10 million people a year. [9] medterms medical dictionary a-z essential list/definition Access to essential medicines is part of the Sustainable Development Goals, in particular Goal 3.8. [13] Support the formulation of evidence-based strategies to ensure affordable access to high-quality, safe and effective medicines and medical devices and to ensure best practices for the implementation of these national strategies; The critical inputs we have identified include active pharmaceutical ingredients from essential drugs and medical countermeasures, as well as ingredients or components that possess unique properties that are essential for evaluating the safety and efficacy of these products. The FDA, in consultation with other federal partners, has been working to develop a list of key drugs and medical countermeasures for drugs and biologics. In addition, medical countermeasures of the instruments are included in the list. Essential medicines, as defined by the World Health Organization (WHO), are medicines that “meet the primary health needs of the population”. [1] These are the drugs that people should have access to in sufficient quantity at all times. Prices should be at a generally affordable level. [2] Since 1977, WHO has published a model list of essential medicines, with the current list (2019) for adult patients comprising more than 400 medicines. [3] Since 2007, a separate list of medicines for paediatric patients has been published.
[4] The omsal lists for adults and children contain a notation indicating that a particular drug is “complementary”, so that there are essentially two lists, the “basic list” and the “complementary list”. The basic list contains a list of minimum drug needs for a basic health system and lists the most effective, safe and cost-effective drugs for priority diseases. Priority conditions are selected on the basis of their current and estimated relevance to public health and the potential for safe and cost-effective treatment. The supplementary list contains essential medicines for priority diseases requiring specific diagnostic or surveillance facilities. When in doubt, drugs may also be listed as complementary in various situations due to higher costs or less attractive cost-effectiveness. The list is important because it forms the basis of national drug policies in more than 155 countries, both developed and developing. Many governments refer to WHO recommendations when making decisions on health spending. Countries are invited to prepare their own lists, taking into account local priorities. More than 150 countries have published an official list of essential medicines. [5] And that remains the 2019 definition [Update].
[1] Some expensive drugs may be included in the list, especially if they are a priority health need and there is good evidence that they are included. The inclusion of very expensive drugs in the list in the hope that prices will be lowered at some point or for advocacy reasons (to encourage more manufacturers), or to try to encourage pharmaceutical authorities/pharmaceutical companies to register the drug, violates the principles of selection of essential drugs. Most of these drugs are still patented, and it would be difficult to obtain from other manufacturers. [4] In addition, this strategy has already been tried and failed. Human immunoglobulin was included in the Model List of Essential Medicines because it was considered vital for certain conditions, but this had little impact on the price. The original WHO definition of 1977 was that they were drugs “of paramount importance, fundamental, indispensable and necessary for the health needs of the population”. [6] The concept was mentioned in one of the ten points of the 1978 Alma Ata Declaration on Primary Health Care […].